Id |
Subject |
Object |
Predicate |
Lexical cue |
T545 |
0-25 |
Sentence |
denotes |
Clinical Research on XBJI |
T546 |
26-313 |
Sentence |
denotes |
Modern clinical studies have shown that XBJI in combination with conventional treatment has therapeutic effects in relevant diseases, such as MERS, human infection with H7N9 avian influenza, CAP, severe pneumonia, systemic inflammatory response syndrome, COPD and sepsis (see Table 3 ). |
T547 |
314-493 |
Sentence |
denotes |
XBJI has been recommended in MERS Diagnosis and Treatment Scheme (Version 2015) and Diagnosis and Treatment Scheme for Human Infection with H7N9 Avian Influenza (Version 1, 2017). |
T548 |
494-662 |
Sentence |
denotes |
Clinical research by Wen Long et al. randomly divided 60 severe COVID-19 patients into routine treatment (n = 20), XBJI 50 ml (n = 20), and XBJI 100 ml (n = 20) groups. |
T549 |
663-835 |
Sentence |
denotes |
On the basis of conventional treatment, XBJI (50 ml) was injected twice a day for 7 days in the XBJI 50 ml group, or 100 ml twice a day for 7 days in the XBJI 100 ml group. |
T550 |
836-972 |
Sentence |
denotes |
After treatment, the white blood cell count (WBC) and lymphocyte count (LYM) of the three groups increased, while CRP and ESR decreased. |
T551 |
973-1103 |
Sentence |
denotes |
Compared with the routine treatment group, the WBC count in the XBJI 100 ml group after treatment significantly increased (×109/L: |
T552 |
1104-1246 |
Sentence |
denotes |
7.12 ± 0.55 vs. 5.67 ± 0.51, p < 0.05), and the levels of CRP and ESR in the XBJI 50 ml and 100 ml groups significantly decreased [CRP (mg/L): |
T553 |
1247-1297 |
Sentence |
denotes |
32.3 ± 4.6, 28.0 ± 6.2 vs. 37.3 ± 5.9; ESR (mm/h): |
T554 |
1298-1351 |
Sentence |
denotes |
45.9 ± 5.7, 40.5 ± 7.4 vs. 55.3 ± 6.6, all p < 0.05]. |
T555 |
1352-1502 |
Sentence |
denotes |
Compared with the XBJI 50 ml group, the increase of WBC, and the decrease of CRP and ESR were more significant in the XBJI 100 ml group [WBC (×109/L): |
T556 |
1503-1543 |
Sentence |
denotes |
7.12 ± 0.55 vs. 5.82 ± 0.49; CRP (mg/L): |
T557 |
1544-1582 |
Sentence |
denotes |
28.0 ± 6.2 vs. 32.3 ± 4.6; ESR (mm/h): |
T558 |
1583-1624 |
Sentence |
denotes |
40.5 ± 7.4 vs. 45.9 ± 5.7, all p < 0.05]. |
T559 |
1625-1671 |
Sentence |
denotes |
The APACHE II score of three groups decreased. |
T560 |
1672-1871 |
Sentence |
denotes |
In the XBJI 100 ml group, the APACHE II score after treatment was significantly lower than those in the routine treatment and XBJI 50 ml groups (12.3 ± 1.5 vs. 16.5 ± 1.6, 15.9 ± 1.4, both p < 0.05). |
T561 |
1872-2128 |
Sentence |
denotes |
After treatment, the 2019-nCoV nucleic acid test in the three groups partly turned negative: nine cases in the routine treatment group, eight cases in the XBJI 50 ml group and nine cases in the XBJI 100 ml group, with no significant differences (p > 0.05). |
T562 |
2129-2206 |
Sentence |
denotes |
The conditions of patients in the three groups were improved after treatment. |
T563 |
2207-2430 |
Sentence |
denotes |
Eight cases in the routine treatment group were transformed into common type and one case into critical type; nine cases and 12 cases in the XBJI 50 ml and 100 ml groups, respectively, were transformed into the common type. |
T564 |
2431-2557 |
Sentence |
denotes |
Patients in the XBJI 100 ml group improved more obviously than in the XBJI 50 ml and routine treatment groups (both p < 0.05). |
T565 |
2558-2687 |
Sentence |
denotes |
The XBJI injection can effectively improve the inflammatory markers and prognosis of severe COVID-19 patients (Wen et al., 2020). |
T566 |
2688-2934 |
Sentence |
denotes |
Clinical research by Qi Fei et al. showed that, of 80 patients with severe pneumonia, those receiving a combination of XBJI and conventional treatment exhibited reduced levels of blood LDH, α1-acid glycoprotein (α1-AG) and α1-antitrypsin (α1-AT). |
T567 |
2935-3048 |
Sentence |
denotes |
Body temperature was reduced significantly and secretion of TNF-α, IL-6, IL-8, and other cytokines was inhibited. |
T568 |
3049-3152 |
Sentence |
denotes |
The total treatment efficiency was up to 80%, compared to 67.5% in the control group (Qi et al., 2011). |
T569 |
3153-3462 |
Sentence |
denotes |
An RCT study comprised of 33 centers and 710 patients conducted by Yuanlin Song et al. showed that XBJI in combination with conventional treatment significantly improved the primary endpoint, pneumonia severity index, in patients with severe CAP (the control group vs XBJI Group, 46.33% vs 60.78%, p < 0.001). |
T570 |
3463-3713 |
Sentence |
denotes |
There was also significantly reduced mortality in 28 days (24.65% vs 15.87%, p = 0.006), the duration of mechanical ventilation was shortened (11 vs 16.5 d, p = 0.012) and length of stay in ICU was reduced (12 vs 16 d, p = 0.004) (Song et al., 2019). |
T571 |
3714-3969 |
Sentence |
denotes |
Mingjin Zhu et al. conducted a meta-analysis of 12 studies with a total of 860 patients and showed that XBJI in combination with conventional treatment was superior to the treatment group in improving total response rate in patients with severe pneumonia. |
T572 |
3970-4150 |
Sentence |
denotes |
Infectious indicators (WBC, CRP, CPIS) and inflammatory cytokine (IL-6, IL-8, TNF-α) levels were reduced, and the average length of stay in hospital was reduced (Zhu et al., 2014). |
T573 |
4151-4492 |
Sentence |
denotes |
Wei Zhao et al. studied 56 patients with systemic inflammatory response syndrome (SIRS) and found that after 7 d treatment with XBJI in combination with conventional treatment, body temperature, WBC, and acute physiology and chronic health evaluation II (APACHE-II) score improved more significantly compared to the control group (p < 0.05). |
T574 |
4493-4711 |
Sentence |
denotes |
Expression of CD4+, CD4+/CD8+, CD14+/HLA-DR (human leukocyte antigen-DR) increased significantly, and the combination regulated the SIRS immune state and improved systemic status of the patients (Zhao W. et al., 2014). |
T575 |
4712-4899 |
Sentence |
denotes |
Clinical research found that XBJI in combination with conventional treatment lowered TNF-α, CRP, and other inflammatory indicators in AECOPD patients and had a certain therapeutic effect. |
T576 |
4900-5113 |
Sentence |
denotes |
In patients with accompanying SIRS, the combination significantly improved cough, expectoration, shortness of breath, and other clinical symptoms, and shortened hospital stay (Chen et al., 2011; Zhu et al., 2019). |
T577 |
5114-5499 |
Sentence |
denotes |
Meta-analysis by Chengyu Li et al. included sepsis patients from 16 RCTs (total 1,144 cases), and evidence of moderate intensity showed that XBJI in combination with conventional treatment effectively reduced the mortality rate of sepsis patients over 28 d (934/1144, p < 0.00001), APACHE-II score (792/1144, p < 0.00001) and body temperature (362/1144, p < 0.00001) (Li et al., 2018). |